PRMT5 and cancer: Finally, the mechanism of action of MTDIA was investigated by assessing PRMT5 activity in treated mice and by generation of an MTAP inhibitor-resistant cell line of FaDu cancer cells, revealing amplification of MAT2A, a known target in MTAP−/− cancers.